bioRxivImmunologyPreprint
Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis
Charlie ChungiD, Elif Ozcelik, J Zhang, Zeli SheniD, Onur EskiocakiD, Yihan QiniD, Jill Habel, Kadir OzleriD, Santhilal SubhashiD, Zakaria Aminzada, Gagan Dev, Libia A. GarciaiD, Scott K. LyonsiD, Timothy Wesley HandiD, David E. Rivadeneira, James G. FoxiD, Peter M.K. WestcottiD, Meri RogavaiD, Semir BeyaziD
Abstract
Colorectal cancer remains a major cause of cancer mortality, and most microsatellite stable tumors derive little benefit from immune checkpoint blockade. Here, we identify a microbiome-dependent mechanism that converts immune-refractory colorectal cancer into a more immunologically responsive state. Using orthotopic mouse models spanning distinct genetic and immunologic contexts, we show that a Helicobacter-containing microbiome suppresses primary tumor growth and limits metastasis. This protective state is associated with increased intratumoral lymphocyte infiltration and stronger effector programs. Mechanistically, microbial exposure induces MHC class II expression in colon cancer cells to promote anti-tumor immunity. Tumor-intrinsic loss of CIITA abrogates microbial protection, whereas enforced CIITA expression is sufficient to increase intratumoral T cell accumulation, restrict progression and metastasis, and sensitize microsatellite-stable tumors to PD-1 and CTLA-4 blockade. In human microsatellite-stable patient-derived organoids, increased cancer-cell MHC-II enhanced interactions with autologous immune cells and increased tumor cell apoptosis. Together, these findings define a microbiome-cancer cell antigen presentation axis that restrains metastasis and overcomes immunotherapy resistance in colorectal cancer.
- organism: mouse
- organism: human
- assay: organoid / primary culture
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multi-compartment immune and tumor cell reprogramming by IFNa2 overcomes colon cancer immunotherapy resistance
Zainab A. Tiamiyu, Patrick Czabala, … Kebin Liu·bioRxiv·Aug 28, 2026
- Immunotherapy efficacy in colorectal cancer is dependent on activation of a microbial-metabolite-immune circuit
L. Mager, R. Burkhard, … K. McCoy·bioRxiv·Feb 26, 2020
- ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancer
Ruize Gao, Kris Van Moer, … Bassam Janji·bioRxiv·Feb 25, 2026
- Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses
Marwa Saad, Alexandra Thoms, … Daniel Mucida·The Journal of Experimental MedicinePeer-reviewed·Oct 26, 2026
- Acquired resistance to immune checkpoint inhibitors is associated with hypoxia and ECM remodeling in colorectal cancer
Astrid Zedlitz Johansen, Hannes Linder, … Daniel Hargbøll Madsen·bioRxiv·Apr 29, 2026
- Colon-specific immune microenvironment regulates cancer progression versus rejection
G. Trimaglio, A.-F. Tilkin-Mariame, … C. Devaud·bioRxiv·Jan 2, 2020